Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
IN8bio, Inc. INAB
$2.38
+$0.22 (9.17%)
На 18:04, 12 мая 2023
+488.24%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
61010478.00000000
-
week52high
3.95
-
week52low
1.02
-
Revenue
0
-
P/E TTM
-2
-
Beta
0.00000000
-
EPS
-1.97000000
-
Last Dividend
0.00000000
-
Next Earnings Date
11 мая 2023 г. в 04:00
Описание компании
IN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidate includes INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation. It also develops INB-400 and INB-300 that is in preclinical Phase for treatment of various solid tumor cancers. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| B. Riley Securities | Buy | Buy | 24 янв 2022 г. |
| Mizuho | Buy | 24 авг 2021 г. | |
| B. Riley Securities | Buy | 23 авг 2021 г. | |
| HC Wainwright & Co. | Buy | 30 авг 2022 г. | |
| B. Riley Securities | Neutral | Buy | 11 ноя 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Fletcher Aaron G.L. | A | 570724 | 8735 | 12 дек 2022 г. |
| Fletcher Aaron G.L. | A | 3727597 | 57052 | 12 дек 2022 г. |
| Fletcher Aaron G.L. | A | 601980 | 9214 | 12 дек 2022 г. |
| Kreis Leslie W. | A | 570724 | 8735 | 12 дек 2022 г. |
| Kreis Leslie W. | A | 3727597 | 57052 | 12 дек 2022 г. |
| Kreis Leslie W. | A | 601980 | 9214 | 12 дек 2022 г. |
| McCall Patrick | A | 59796 | 59796 | 21 окт 2022 г. |
| Goswami Trishna | A | 68427 | 68427 | 21 окт 2022 г. |
| Ho William Tai-Wei | A | 83265 | 83265 | 21 окт 2022 г. |
| Lamb Lawrence | A | 62826 | 62826 | 21 окт 2022 г. |
Новостная лента
IN8bio to Present at the B. Riley Securities' 3rd Annual Virtual Oncology Conference
GlobeNewsWire
17 янв 2023 г. в 07:00
NEW YORK, Jan. 17, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company discovering and developing innovative gamma-delta T cell therapies, today announced William Ho, CEO and co-founder, will present a company overview at the B. Riley Securities' 3rd Annual Oncology Conference on Wednesday, January 18, 2023 at 12:00pm ET.
IN8bio to Present at Biotech Showcase 2023 in San Francisco
GlobeNewsWire
03 янв 2023 г. в 07:00
NEW YORK, Jan. 03, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company discovering and developing innovative gamma-delta T cell therapies, today announced William Ho, CEO and co-founder, will present at Biotech Showcase 2023 on Monday, January 9, 2023, and will also participate in a panel on Tuesday, January 10, 2023, at the Hilton San Francisco Union Square Hotel in San Francisco, CA.
IN8bio to Present Positive Early Data from Ongoing Phase 1 Study of INB-100 at the 64th American Society of Hematology Annual Meeting
GlobeNewsWire
03 ноя 2022 г. в 09:10
NEW YORK, Nov. 03, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company discovering and developing innovative gamma-delta T cell therapies that utilize its DeltEx platform, today announced positive early data from the ongoing Phase 1 trial evaluating INB-100, an allogeneic gamma-delta T cell therapy, in patients with high-risk acute myeloid leukemia (AML) undergoing haploidentical hematopoietic stem cell transplant (HSCT) have been selected for a poster presentation at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition taking place December 10-13, 2022.
IN8bio to Present at November Investor Conferences
GlobeNewsWire
01 ноя 2022 г. в 07:30
NEW YORK, Nov. 01, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company discovering and developing innovative gamma-delta T cell therapies that utilize its DeltEx platform, today announced William Ho, CEO and co-founder, will be presenting at two investor conferences in November.
IN8bio to Present at Cantor Oncology & HemOnc Conference
GlobeNewsWire
27 сент 2022 г. в 07:30
NEW YORK, Sept. 27, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company discovering and developing innovative gamma-delta T cell therapies that utilize its DeltEx platform, today announced that William Ho, IN8bio's Chief Executive Officer, will be a speaker on the “Cell Therapy in Solid Tumors” panel at the Cantor Oncology & HemOnc Conference. The panel will take place at 1:45 p.m. ET on September 28, 2022.